Bausch Health Companies (NYSE:BHC) has been given a $29.00 price target by Piper Jaffray Companies in a research note issued to investors on Tuesday, TipRanks reports. The firm currently has a “buy” rating on the stock. Piper Jaffray Companies’ price target suggests a potential upside of 31.04% from the company’s current price.
A number of other brokerages have also recently commented on BHC. SunTrust Banks initiated coverage on shares of Bausch Health Companies in a research note on Tuesday, March 19th. They set a “buy” rating and a $30.00 price target on the stock. Cantor Fitzgerald set a $32.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research note on Friday, May 31st. Wells Fargo & Co set a $9.00 target price on shares of Bausch Health Companies and gave the stock a “sell” rating in a research note on Friday, May 17th. Bank of America reiterated an “underperform” rating and issued a $18.00 target price on shares of Bausch Health Companies in a research note on Wednesday, March 20th. Finally, Zacks Investment Research upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Friday, April 5th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $27.65.
Shares of BHC stock traded up $0.45 during trading on Tuesday, reaching $22.13. 3,765,163 shares of the company’s stock traded hands, compared to its average volume of 4,184,045. The stock has a market capitalization of $7.63 billion, a P/E ratio of 5.50, a PEG ratio of 0.48 and a beta of 0.61. The company has a current ratio of 1.08, a quick ratio of 0.83 and a debt-to-equity ratio of 8.61. Bausch Health Companies has a 1 year low of $17.20 and a 1 year high of $28.45.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Pinnacle Associates Ltd. increased its stake in Bausch Health Companies by 27.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 10,150 shares of the company’s stock valued at $187,000 after purchasing an additional 2,200 shares in the last quarter. Westside Investment Management Inc. increased its stake in Bausch Health Companies by 1,599.3% during the 4th quarter. Westside Investment Management Inc. now owns 12,150 shares of the company’s stock valued at $224,000 after purchasing an additional 11,435 shares in the last quarter. Stevens Capital Management LP bought a new stake in Bausch Health Companies during the 4th quarter valued at about $2,232,000. Commerzbank Aktiengesellschaft FI increased its stake in Bausch Health Companies by 2.8% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 762,222 shares of the company’s stock valued at $14,078,000 after purchasing an additional 21,077 shares in the last quarter. Finally, Enlightenment Research LLC bought a new stake in Bausch Health Companies during the 4th quarter valued at about $133,000. Institutional investors and hedge funds own 53.67% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: What is the Coverage Ratio?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.